Escolar Documentos
Profissional Documentos
Cultura Documentos
Polyneuropathies
Michelle L. Mauermann, M.D.,1 and Ted M. Burns, M.D.2
ABSTRACT
In this article, we present an easy-to-remember method of evaluating neuropathies. Our proposed method is based on asking four questions about the neuropathy and
the patient: What?, Where?, When?, and What setting? Answering these questions
helps characterize the neuropathy, and this characterization enables the clinician to develop
a focused differential diagnosis and plan. After presenting this approach to evaluating
neuropathy, we discuss many of the most common chronic axonal neuropathies in the
context of this paradigm. Acquired demyelinating neuropathies and inherited neuropathies
are discussed in other articles in this issue of Seminars in Neurology.
KEYWORDS: Peripheral neuropathy, polyneuropathy, axonal neuropathies
@mayo.edu).
Neuromuscular Disorders; Guest Editor, Ted M. Burns, M.D.
Semin Neurol 2008;28:133151. Copyright # 2008 by Thieme
Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001,
USA. Tel: +1(212) 584-4662.
DOI 10.1055/s-2008-1062270. ISSN 0271-8235.
WHAT?
The question What? refers to which nerve fiber modalities (motor, sensory, autonomic, or a combination) are
involved. At a minimum, the identification of sensory
nerve involvement allows the clinician to exclude other
neuromuscular diseases not associated with sensory dysfunction, such as myopathies, neuromuscular transmission disorders or disease of the anterior horn cell (e.g.,
133
134
2008
Figure 1 A suggested construct for the approach to neuropathy, using the what, where, when, and what setting approach
to characterize the neuropathy and place the it into a presumed etiologic category. PNSS, positive neuropathic sensory
symptoms; CMT, Charcot-Marie-Tooth; HMSN, hereditary motor and sensory neuropathies; GBS, Guillain-Barre syndrome;
HNPP, hereditary neuropathy with liability to pressure palsies; CIDP, chronic inflammatory demyelinating polyradiculoneuropathy; HSN, hereditary sensory neuropathy; MMN, multifocal motor neuropathy.
WHERE?
Where? refers to the distribution of nerve involvement
in terms of (1) the global distribution throughout the
body and (2) the distribution of involvement along the
nerve(s). It is especially critical to determine whether a
neuropathic process is length-dependent (i.e., distal) or
not (Fig. 1). Length-dependent neuropathies manifest
first in the feet and are symmetrical. Nonlength-dependent neuropathies are not necessarily first evident in
the feet. Whether a neuropathy is symmetrical or not is
another diagnostic watershed (Fig. 1). Symmetrical neuropathies are usually metabolic, toxic, idiopathic, or
inherited, whereas asymmetrical neuropathies are often
immune-mediated or infectious. Some examples of non
length-dependent neuropathies are polyradiculopathies
(e.g., Lyme neuroborreliosis, cytomegalovirus [CMV]
polyradiculitis, sarcoid polyradiculopathy), polyradiculoneuropathies (e.g., GBS, CIDP, diabetic and nondiabetic
radiculoplexus neuropathy), dorsal root polyganglionopathies (e.g., paraneoplastic subacute sensory neuronopathy, immune-mediated sensory ganglionopathy),
plexopathies (often immune-mediated), and mononeuritis multiplex (usually caused by vasculitis). There are, of
course, exceptions, such as the clinical presentation of
recurrent, painless, transient mononeuropathies in hereditary neuropathy (with liability to pressure) palsy
(HNPP)23 and the asymmetrical or unilateral brachial
plexopathy of hereditary neuralgic amyotrophy (which,
although being inherited, likely has an immune-mediated
component in its pathogenesis).24
WHEN?
When? refers to the temporal evolution of the neuropathy. Because of confusion over what is meant by acute,
subacute and chronic, we prefer to describe symptom
onset based on whether the neuropathic symptoms had a
compelling, definite date of onset. Most immune-mediated or infectious (Lyme neuroborreliosis) neuropathies
have a definite date of onset. A less-exact date of onset
suggests a toxic/metabolic, inherited, or idiopathic etiology (Fig. 1). The tempo following symptom onset is also
an important consideration. Symptom onset and tempo
often correlate in a predictable manner, owing in large
part to the underlying mechanism. For example, patients
with GBS present with a definite date of onset followed
by rapid progression of impairment and disability. The
symptom onset date of an inherited neuropathy, however,
usually can only be grossly estimated, and the progression
following symptom onset is almost always gradual.
WHAT SETTING?
What setting? refers to the process of elaborating the
unique clinical circumstance of the patient. This is done
by determining what in the patients past medical history, medication list, social history, family history, and
the review of systems may be germane. An understanding of the significance of these clinical factors requires
knowledge of the risk factors of neuropathy and knowledge of the clinical features of the diseases that are risk
factors for neuropathy. When constructing the patients
clinical setting, the clinician must remember to consider
first the common causes of neuropathy (e.g., diabetes,
alcohol abuse, genetic causes) and search aggressively for
any clinical clues that might suggest these etiologies.
This is perhaps most important when evaluating a
patient for an inherited neuropathy, given that one third
to one half of all neuropathies are likely inherited. At a
minimum, the clinician should ask specifically about
each first-degree relative: Please tell me about your
siblings, and did any sibling have complaints similar to
yours?; Did either parent or any sibling have a problem
with his or her feet or with walking?; Do any of your
siblings or parents have high arches or curled toes? The
patient should be queried also about cousins, aunts, and
uncles. Family members should be examined whenever
possible. By asking specific questions about family and
examining relatives whenever possible, clues are often
uncovered that would have otherwise never been mentioned by the patient, in part because family members
often have alternative explanations for the symptoms
(age, arthritis, etc.). For example, in one of our patients,
a delay in diagnosis of inherited neuropathy occurred
because the mother was queried about symptoms of
neuropathy but not examined at the sons initial visit;
it was only at follow-up that the mother was examined
and subsequently diagnosed with neuropathy, prompting
135
136
2008
ELECTRODIAGNOSTIC TESTING
The fifth step for characterizing a neuropathy uses
electrodiagnostic testing. Electrodiagnostic testing can
confirm (or rarely refute) the clinical characterization in
terms of what and where, as well as provide another view
of the temporal evolution (when). Electrodiagnostic testing can also characterize the neuropathy as being primarily axonal or demyelinating. The metabolic, toxic, and
idiopathic neuropathies usually manifest with prominent
axonal injury, whereas immune-mediated and inherited
neuropathies may be either predominantly axonal or predominantly demyelinating. For example, GBS and CIDP
are two relatively common immune-mediated neuropathies that are predominantly demyelinating.8,2730
CMT1, the most common inherited sensorimotor neuropathy, is predominantly demyelinating, whereas CMT2
is predominantly axonal.31 Electrodiagnostic testing can
also assess for subclinical involvement and provide baseline
parameters in case future electrodiagnostic testing is
necessary to monitor the patients course.
Chloroquine
Colchicine
Cardiovascular medications
Amiodarone
Hydralazine
Perhexiline
Metabolic Etiologies
Propafenone
Psychiatric and sedative medications
Disulfiram
Other medications
Pyridoxine (vitamin B6)
Phenytoin
From Lewis RA. Toxic and deficiency neuropathies. Continuum.
Lifelong Learning in Neurology 2003;9:160181.
Diabetes Mellitus
The 2003 American Diabetic Association (ADA) guidelines defined impaired fasting glucose (IFG) as a plasma
glucose level greater than > 100 and < 126 mg/dL and
impaired glucose tolerance (IGT) as a 2-hour glucose
level between 140 and 199 mg/dL after a 75-g oral
glucose load. Both IFG and IGT are indicative of
impaired glucose metabolism. Impaired glucose metabolism is associated with macrovascular disease such as
myocardial infarction, stroke, and peripheral vascular
disease as well as microvascular disease such as retinopathy and nephropathy.39 In addition, impaired glucose
metabolism has recently been suggested as a cause of
chronic idiopathic axonal polyneuropathy (CIAP). Some
feel that it might be representative of an earlier form of
diabetic sensory or sensorimotor neuropathy associated
with prolonged hyperglycemia.
The association between impaired glucose metabolism and neuropathy has been suggested by several
retrospective studies.4043 These studies showed an increased incidence of DM and impaired glucose metabolism with CIAP, and this was most commonly
associated with a painful sensory predominant neuropathy.40,41,43,44 Some have suggested the neuropathy of
impaired glucose metabolism more often involves predominantly small fibers compared with the neuropathy
associated with diabetes and chronic hyperglycemia,
which more commonly involves both small and large
fibers.39,42 However, others have shown associations
with either a sensory (small or large) or sensorimotor
(small and large) neuropathy.43 The reported limitations
of these studies include inclusion of preselected patients
with certain types of neuropathies, referral bias, insufficient exclusion of other causes of neuropathy, and use of
previously published control populations, of which the
reported incidence of impaired glucose metabolism may
not be accurate or representative of the cohort with
disease.45 Sumner and colleagues reported that the
neuropathy associated with impaired glucose metabolism may be an earlier, less severe form of diabetic
neuropathy, based on the demonstration of comparatively mild abnormality with respect to intraepidermal
nerve fiber density, sural nerve amplitude, sural nerve
137
138
2008
Uremia
ASSOCIATION WITH NEUROPATHY
The neuropathy in uremia is distally predominant, symmetrical, and slowly progressive. Symptoms include negative neuropathic sensory symptoms and positive
neuropathic sensory symptoms such as paresthesias and
burning feet.50,51 Restless legs, cramps, and weakness are
also common. Both small and large-fiber sensory loss and
motor involvement occur.50,51 Other systemic disorders
associated with renal failure must be alternatively considered as causing the neuropathy, such as DM, amyloidosis, or vasculitis.51 Drug-induced neuropathy also
needs to be considered in this population of patients.
The diagnosis should be strongly considered in
patients with end-stage renal failure with a creatinine of
5 mg/dL or higher or creatinine clearance of less than 12
mL/min.50,51 Electrodiagnostic testing may demonstrate
slightly prolonged distal motor latencies, slowed con-
Thiamine Deficiency
ASSOCIATION WITH NEUROPATHY
Thiamine (vitamin B1) deficiency is seen most commonly in chronic alcohol abuse, recurrent vomiting, total
parenteral nutrition, and following weight reduction
surgery (bariatric surgery).53 Deficiency also can occur
in individuals with chronic gastrointestinal problems or
those who are elderly, on cancer treatment, or those who
are receiving diuretic therapy. Severe deficiency causes
congestive heart failure (wet beriberi), peripheral neuropathy (e.g., dry beriberi), Wernickes encephalopathy,
and Korsakoffs syndrome. Symptoms and signs of mild
to moderate thiamine deficiency are nonspecific. Moderate deficiency can affect intellectual performance and
well-being in the absence of other clinical symptoms.
Thiamine-deficiency neuropathy should be considered
in patients who abuse alcohol or have had bariatric
surgery (e.g., for morbid obesity). Extreme weight loss
following bariatric surgery places patients at risk of
malnutrition, including thiamine deficiency, particularly
if follow-up with a nutritionist is suboptimal. In a large
series of patients who underwent weight reduction
bariatric surgery, 6% developed neuropathy, and in
some of these cases it appeared that nutritional deficiency, including thiamine deficiency, was pathogenic.54
Patients with thiamine deficiency may complain of
fatigue, irritability, and muscle cramps that develop
within days to weeks of nutritional deficiency.53
NEUROPATHY
Hypothyroid
ASSOCIATION WITH NEUROPATHY
Cobalamin Deficiency
ASSOCIATION WITH NEUROPATHY
TOXIC ETIOLOGIES
What? Sensory or sensorimotor; positive neuropathic sensory symptoms including pain. Autonomic
nerve involvement not uncommon.
Where? Distal, symmetrical (i.e., length dependent), or symmetrical but not distal if toxin causes a
sensory neuronopathy (dorsal root polyganglionopathy).
When? Varies, depending on toxin and dose.
Patients with alcoholic neuropathy may be able to report
a month or season of onset but typically not an exact date
of onset. Patients with other toxic neuropathies may
report a definite date of onset if exposure was acute and
taken at a high dose. Progression varies based on toxin
and dose, and usually stabilizes or improves with cessation. Consider comorbidities (e.g., alcoholism) and
therapies of comorbidities.
What setting? No family history of neuropathy,
no foot deformities, onset in adulthood following exposure; consider comorbidities and treatments (e.g.,
chemotherapy) and other risk factors (e.g., accidental
exposures). Systemic symptoms (e.g., weight loss, gastrointestinal) are common.
NEUROPATHY
139
140
2008
length-dependent, sensory, predominant axonal neuropathy.61 However, except for neuropathy caused by
alcohol, toxic neuropathies are probably overinvestigated and overdiagnosed3; in fact, they probably represent well below 5% of cases of chronic distal,
symmetrical, sensory, or sensorimotor neuropathies.62
Nonetheless, prompt identification of a toxic neuropathy is important because removal of any harmful
agent may lead to improvement or resolution of neuropathy. The list of potentially offending agents that we
provide in Table 2 is long and includes many common
medications and agents that the population is frequently
exposed to in low doses. The relative risk estimate of the
drug causing neuropathy must be considered in the
context of the overall prevalence of neuropathy in
the general population, the likelihood the neuropathy
has an alternative cause, temporal association of drug
and neuropathy, the degree of impairment, disability
and impaired quality of life, and the salutary effects of
the drug. It is our experience that more often than not
the commonly prescribed drugs are not the cause of a
neuropathy. The most frequent offenders are some of
the chemotherapeutic agents and some of the anti-HIV
drugs. When a drug or toxin is suspected, the exposure
must be verified, the symptoms must be temporally
related to the toxin, and other causes must be ruled
out. Furthermore, some clinical improvement or at least
stabilization should occur following removal of the
offending agent, although this may take months to years
to occur.63 Medication-induced neuropathy is more
common than industrial and environmental neuropathies. The neuropathy of heavy metal intoxication is
very rare and is usually accompanied by a combination of
gastrointestinal, hematologic, and central nervous systems problems. Although heavy metal analysis is routinely obtained for evaluation of neuropathy, it is rarely
ever useful unless there is a strong suspicion for heavy
metal exposure and the neuropathy is acute or subacute.1
Chemicals that can, although rarely, cause neuropathy
at toxic doses include acrylamide, carbamates, carbon
disulfide, ethylene glycol, organophosphates, and hexacarbons.64
Alcohol Abuse
ASSOCIATION WITH NEUROPATHY
of patients had electrophysiological evidence of polyneuropathy and one fourth had autonomic neuropathy.67
The direct toxic effect of alcohol on peripheral nerves
seems to be the most important etiology.68 Other
investigators prospectively identified neuropathy in
58% of alcoholics, which correlated with the age of the
patient and the duration of alcohol use.68
NEUROPATHY
INFECTIOUS ETIOLOGIES
What? Sensory or sensorimotor; positive neuropathic sensory symptoms, especially pain.
Where? Depends on the infection. HIV neuropathy often presents with a distal, symmetrical distribution, but others (e.g., Lyme, hepatitis C virus [HCV],
sarcoidosis, leprosy, sporotrichosis69) usually do not.
Lyme and sarcoidosis often present with painful, asymmetrical polyradiculoneuropathy. HCV associated with
mixed cryoglobulinemia and sporotrichosis may present
with mononeuritis multiplex, asymmetrical distal-predominant neuropathy or even a distal, symmetrical
polyneuropathy.
When? Definite date of onset is typical, particularly for Lyme and sarcoidosis.
What setting? No family history of neuropathy,
no foot deformities, onset in adulthood following exposure; consider risk factors (e.g., HIV risk factors, tick
bite, previous transfusions, residence in endemic areas,
environmental risks). Systemic symptoms (e.g., weight
loss, rash, fatigue, fevers) are common.
Hepatitis C Virus
ASSOCIATION WITH NEUROPATHY
Hepatitis C virus is the most common chronic bloodborne viral infection in the United States. The third
National Health and Nutrition Examination Survey
(NHANES) found that 1.8% of Americans have been
infected with HCV, and most are chronically infected.70
Neuropathy in HCV may affect 10% of patients,71,72
and the prevalence increases to up to 30% in those
positive for mixed (type II or type III) cryoglobulins.73
The mechanism of nerve injury may be virus-triggered
nerve microvasculitis rather than direct viral nerve infection with in situ replication.71 The exact pathophysiological role of cryoglobulins in HCV neuropathy is
unclear. Some investigators have posited that intravascular deposits of cryoglobulins lead to interference of the
vasa nervorum microcirculation.73 The finding that not
all HCV patients with neuropathy have detectable serum
cryoglobulins raises the question of whether there are
other mechanisms for nerve injury.72
NEUROPATHY
In HCV neuropathy, positive neuropathic sensory symptoms such as burning, prickling, and pain are prominent.74 The neuropathy in HCV with mixed
cryoglobulinemia may present as a distal, asymmetrical
(or less commonly symmetrical), sensory, or sensorimotor polyneuropathy71,73 or as mononeuritis multiplex.71
Patients with HCV neuropathy and mixed cryoglobulinemia may be otherwise asymptomatic or report
accompanying symptoms such as fatigue, loss of appetite,
nausea, weight loss, fever, weakness, and arthralgias.71,75
Palpable purpura on the ankles, for example, is common
and should be looked for on examination.76
The primary serologic screening assay for HCV
infection is an enzyme immunoassay that is able to
detect antibodies within 4 to 10 weeks after infection,
missing only 0.5 to 1% of cases. Recombinant immunoblot assays are used to confirm the serologic
assay. HCV RNA tests are used to confirm viremia.70
Cryoglobulins are single (type I) or mixed (types II
and III) immunoglobulins (Igs) that precipitate as the
serum is cooled below core body temperature.77 Blood
should be collected in a syringe prewarmed to 378C.78
It should be allowed to clot for 30 minutes and
then be centrifuged at 378C. The plasma and serum
are separated and both incubated for 24 hours at 18C.
The samples are assessed at 24 hours and 7 days
for precipitate78 because type I and type II cryoglobulins usually precipitate quickly, whereas type III cryoglobulins can take up to 7 days. The precipitates are then
characterized and typed using immunofixation. The electrodiagnostic study will demonstrate an axonal, sensorimotor neuropathy that is often asymmetrical71 or
involves multiple nerves as a mononeuritis multiplex.
Lyme Disease
INFECTION AND ASSOCIATION WITH NEUROPATHY
141
142
2008
concentration.84 Cerebrospinal fluid (CSF) Lyme polymerase chain reaction (PCR) has 40 to 50% sensitivity
and 97% specificity.81
ment or enhancement of affected nerves.93 Electrodiagnostic testing usually reveals an asymmetrical, multifocal
axonal process.93,95
Sarcoidosis
NEUROPATHY
NEUROPATHY
Leprosy
ASSOCIATION WITH NEUROPATHY
Leprosy remains the most important infectious neuropathy worldwide with 3 million active cases.105 It is
very prevalent in Southeast Asia, India, Africa, and
Central and South America. Leprosy is transmitted
through nasal droplets and then spreads by hematogenous dissemination to skin and nerves with an incubation period of up to many years.106,107
NEUROPATHY
IMMUNE-MEDIATED
What? Sensory or sensorimotor; positive neuropathic sensory symptoms, especially pain.
Where? Usually not length dependent. GBS and
CIDP typically present as a polyradiculoneuropathy.
Many other immune-mediated neuropathies present
with an asymmetrical distribution.
When? Definite date of onset is common.
What setting? No family history of neuropathy,
no foot deformities, onset in adulthood; patients may
have symptoms suggestive of more widespread autoimmunity (e.g., sicca complex) or may have a diagnosis
of an autoimmune disease (e.g., Sjogrens or rheumatoid
arthritis). Systemic symptoms (e.g., weight loss, rash,
fatigue, fevers) are common. Many autoimmune diseases
affect women more than men.
Vasculitis
ASSOCIATION WITH NEUROPATHY
143
144
2008
Mononeuritis multiplex, the most common presentation of vasculitic neuropathy, is acute to subacute in
presentation and almost always painful. It can begin
in the upper or lower extremities, typically at watershed zones such as the sciatic nerve at the mid-thigh
and nerves in the mid-upper arm.119 Vasculitis less
commonly presents as a painful asymmetrical or
distal, symmetrical, sensorimotor polyneuropathy.110,111 Systemic vasculitis almost always occurs
in patients in the setting of constitutional symptoms
such as weight loss, respiratory symptoms, hematuria,
abdominal pain, rash, myalgias, arthralgias, fever, and
night sweats.110
Laboratory evaluation of suspected cases of vasculitic neuropathy should include a complete blood
count (CBC), metabolic panel (electrolytes, blood
urea nitrogen, creatinine, and glucose), erythrocyte
sedimentation rate (ESR), C-reactive protein (CRP),
antinuclear antibody (ANA), rheumatoid factor (RF),
proteinase 3 (PR3)/cytoplasmic (c)-staining antineutrophilic cytoplasmic autoantibody (ANCA) and myeloperoxidase (MPO)/perinuclear (p)-staining ANCA,
hepatitis B and C panels, and cryoglobulins. Serum
complement determinations are indicated in suspected
mixed cryoglobulinemia or systemic lupus syndromes.
It is also often appropriate to check extractable nuclear
antigen, serum ACE level, serum protein electrophoresis, and HIV. CSF analysis is usually not helpful,
except to aid in the investigation of mimickers, including infectious (e.g., Lyme) or other inflammatory etiologies (e.g., carcinomatous root involvement).111 In
systemic vasculitic neuropathy, serological testing is
abnormal and helps further define the etiology or
syndrome. In nonsystemic vasculitic neuropathy, the
ESR or CRP may be slightly elevated, but other
markers of inflammation or systemic disease are normal.111 Electrodiagnostic testing often demonstrates
acute to subacute sensory and motor axonal injury in a
patchy multifocal pattern. Sensory nerve biopsy (sural
nerve or superficial peroneal nerve) should be performed to establish the diagnosis.120
Sjogrens Syndrome
ASSOCIATION WITH NEUROPATHY
fibers with increased axonal degeneration.128 The electrodiagnostic test results for patients with painful
sensory neuropathy without ataxia is in keeping with
a predominantly small-fiber neuropathy (e.g., normal
results).128
PARAPROTEINEMIAS
What? Sensorimotor; often with positive neuropathic sensory symptoms.
Where? Variable, but often length dependent.
When? May be gradual onset.
What setting? No family history of neuropathy,
no foot deformities, onset in adulthood; patients may
have systemic symptoms (e.g., weight loss, fatigue) if
paraproteinemia is malignant.
145
146
2008
When encountering a patient with a neuropathy associated with a paraprotein, such as MGUS, the clinician
must try to determine whether the neuropathy is idiopathic or due to another cause, and thus its association
with the paraprotein is simply a chance association, or
whether the neuropathy is secondary to the process
causing the paraprotein. Neuropathies associated with
paraproteinemias include distal acquired demyelinating
symmetrical with M-protein (DADS-M) neuropathy
(also known as a CIDP variant), neuropathy associated
with primary systemic amyloidosis, neuropathy of POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes), neuropathy
associated with Waldenstroms macroglobulinemia, neuropathy associated with multiple myeloma, and neuropathy associated with Castlemans syndrome. The
history and electrodiagnostic testing are particularly
helpful in sorting this out: accompanying systemic
symptoms raise concern for primary systemic amyloidosis, POEMS, or malignancy; autonomic symptoms and
signs are common in primary systemic amyloidosis;
electrodiagnostic testing features of primary demyelination are commonly seen in neuropathies of DADS-M,
POEMS, Waldenstroms macroglobulinemia and
Castlemans syndrome, whereas the neuropathy is
usually axonal when associated with primary systemic
amyloidosis. The demyelinating neuropathies associated with a paraprotein are not discussed further in this
article. Please refer to David Sapersteins article,
Chronic Acquired Demyelinating Polyneuropathies,
in this issue of Seminars of Neurology for an excellent
discussion of DADS-M and many other chronic
acquired demyelinating neuropathies.
PARANEOPLASTIC SYNDROMES
What? Variable. May be sensory (e.g., sensory
neuronopathy), sensorimotor or, rarely, predominantly
motor. Concomitant autonomic neuropathy (e.g., gastrointestinal dysmotility) is common. Positive neuropathic sensory symptoms are typical.
Where? Usually not length dependent, often
asymmetrical.
When? Definite date of onset with rapid progression; usually leading to severe impairments.
What setting? No family history of neuropathy,
no foot deformities, onset usually in adulthood; smoking
history; patients may have systemic symptoms (e.g.,
weight loss, fatigue).
Neuropathy
The paraneoplastic neuropathy may present as a sensory
ganglionopathy or sensory-predominant neuropathy,
sometimes associated with autonomic neuropathy. Subacute onset with rapid progression is typical.13,148 Sensory symptoms such as paresthesias, dysesthesias, and
pain predominate, whereas motor involvement is typically mild and may only be found on electrodiagnostic
evaluation.14,147 There may be prominent upper extremity involvement and pseudoathetosis.13,14 Autonomic
involvement is found in up to one fourth of patients,
most commonly orthostatic hypotension and gastroparesis, although many other dysautonomic symptoms may
manifest.1315 Most patients develop severe disease with
significant disability.150
Laboratory evaluation should be directed toward
paraneoplastic antibodies, of which there are many.
These antibodies usually do not predict the neurological
syndrome but rather predict the malignancy, and the
coexistence of antibodies can also be used to predict the
underlying malignancy.151 The sensitivity and specificity
of the ANNA-1 antibody is thought to be 80% and
98%, respectively.15 The sensitivity and specificity of the
other antibodies have not yet been established. Electrodiagnostic testing often shows axonal sensory or sensorimotor neuropathy or sensory ganglionopathy.14 Any
workup should also include investigation for a malignancy.13,14,148,150 With a paraneoplastic syndrome associated with SCLC, the tumor is limited to the
mediastinum in 90% of patients.13,148 The workup
should begin with chest radiograph. If this is negative,
the clinician should proceed to computed tomography
(CT), MRI, or positron emission tomography (PET)
imaging.148,149,152,153 In the other antibody syndromes,
the workup should be directed toward the recognized
associated malignancies.
INHERITED NEUROPATHIES
What? Sensory or sensorimotor; often only negative neuropathic sensory symptoms (particularly so for
CMT1A, the most common inherited neuropathy).
Where? Distal, symmetrical (i.e., length dependent).
When? Insidious onset without definite date.
Very slowly progressive.
147
148
2008
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
149
150
2008
151